December 2021

December 25, 2021

As the most common trigeminal autonomic cephalalgia, this unilateral and severe headache is accompanied by ipsilateral autonomic features and is often challenging to treat.

December 24, 2021

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

December 23, 2021

After years of research showing that it demonstrates similar benefit to alteplase, tenecteplase’s benefit in a large patient cohort with acute ischemic stroke will be tested in the TIMELESS trial.

December 22, 2021

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

December 21, 2021

As Dravet syndrome is often nonresponsive to existing therapeutics, it can be a challenge to treat, and this refractory nature creates a great need for novel, innovative, and safe antiepileptic drugs for its treatment.

December 20, 2021

The diagnosis of Parkinson disease may seem straightforward at first, requiring neurologists to rely on their eyes and hands, but the treatment process can present challenges for both physicians and patients.

October 27, 2021

Data further investigated the impact of how individual disease-modifying therapies affect outcomes for this patient population.

October 27, 2021

All told, 48% of patients with MS reported that their most common primary person for guidance on cannabis use in MS was themself or no one, followed by a dispensary professional and MS physician.

October 26, 2021

Investigators provided 4 strategies for health care providers to implement when speaking to patients with MS, in an effort to improve communication between both parties.

October 26, 2021

Real-world data from a single-center study with more than 4 years of follow-up showed similar rates of moderate infections and malignancies to the general population with multiple sclerosis.

October 26, 2021

The results demonstrate a positive change in patients with previous disease-modifying drug failures.

October 25, 2021

Patient data were evaluated over a 3-year period, with analyses from baseline, year 1, and year 2 presented at previous CMSC meetings.

October 25, 2021

Both diets resulted in patients with MS reporting significant changes on Perceived Deficits Questionnaire scores for fatigue and cognitive dysfunction after 12 weeks of intervention.